Aardvark Therapeutics Shares Plunge After Trial Halt
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy AARD?
Source: PRnewswire
- Trial Suspension: On March 2, 2026, Aardvark Therapeutics announced the halt of its HERO trial for ARD-101 in Prader-Willi Syndrome patients, resulting in a 56% drop in share price, equating to a loss of $7.02 per share, indicating a severe blow to investor confidence in the company's future.
- Safety Risk Warning: The company cited “reversible cardiac observations” as the reason for pausing the trial, a revelation that not only dashed investor expectations but also raised concerns among analysts, prompting several to sharply reduce or suspend their price targets for the stock.
- Investor Investigation Launched: In light of the drastic market reaction, Hagens Berman law firm has initiated an investigation into whether Aardvark misled investors regarding the safety and efficacy data of ARD-101, potentially exposing the company to legal risks.
- FDA Communication Issues: Aardvark previously claimed good communication with the FDA and emphasized ARD-101's “tolerable safety profile,” but this incident has raised questions about the transparency of its disclosures, which could impact future investor trust and the company's reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AARD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AARD
Wall Street analysts forecast AARD stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.900
Low
18.00
Averages
33.00
High
50.00
Current: 3.900
Low
18.00
Averages
33.00
High
50.00
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aardvark Therapeutics Shares Plunge After Trial Halt
- Trial Suspension: On March 2, 2026, Aardvark Therapeutics announced the halt of its HERO trial for ARD-101 in Prader-Willi Syndrome patients, resulting in a 56% drop in share price, equating to a loss of $7.02 per share, indicating a severe blow to investor confidence in the company's future.
- Safety Risk Warning: The company cited “reversible cardiac observations” as the reason for pausing the trial, a revelation that not only dashed investor expectations but also raised concerns among analysts, prompting several to sharply reduce or suspend their price targets for the stock.
- Investor Investigation Launched: In light of the drastic market reaction, Hagens Berman law firm has initiated an investigation into whether Aardvark misled investors regarding the safety and efficacy data of ARD-101, potentially exposing the company to legal risks.
- FDA Communication Issues: Aardvark previously claimed good communication with the FDA and emphasized ARD-101's “tolerable safety profile,” but this incident has raised questions about the transparency of its disclosures, which could impact future investor trust and the company's reputation.
See More
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56%
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, the suspension of its HERO trial, resulting in a share price drop of $7.02 (-56%), a decision driven by serious safety risks identified as 'reversible cardiac observations,' which directly undermined investor confidence in the company's future prospects.
- Investor Investigation Launched: In light of the severe market reaction, Hagens Berman law firm has initiated an investigation into whether Aardvark misled investors regarding the safety and efficacy disclosures of ARD-101, potentially violating federal securities laws, further exacerbating investor anxiety.
- FDA Communication Issues: Aardvark previously claimed smooth communication with the FDA and emphasized ARD-101 as a 'first-in-class' drug; however, the trial suspension has raised questions about the transparency and accuracy of its communications with the FDA, which could impact future regulatory approval processes.
- Analyst Downgrades: Following the emergence of cardiac safety signals, several analysts have begun to sharply reduce or suspend their price targets for Aardvark, reflecting a pessimistic sentiment in the market regarding the company's outlook, which may lead to further declines in share price.
See More
Aardvark Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud or unlawful business practices, which could undermine investor confidence and lead to further stock price declines.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations found in a healthy volunteer study, potentially delaying product launch timelines and impacting future revenues.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price plummeted by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, reflecting extreme market pessimism regarding the company's outlook.
- Legal Implications: Pomerantz LLP, a prominent securities litigation firm, may initiate a class action lawsuit against Aardvark if the investigation confirms wrongdoing, which would severely impact the company's reputation and financial standing.
See More
AARDVARK THERAPEUTICS INC: B. RILEY LOWERS TARGET PRICE FROM $32 TO $8
- Target Price Adjustment: B. Riley has cut the target price for Aardvark Therapeutics from $32 to $8.
- Market Impact: This significant reduction reflects a reassessment of the company's market position and potential.
See More
Aardvark Therapeutics Reports Wider Losses in Q4 and FY2025
- Dismal Financial Results: Aardvark Therapeutics reported a net loss of $17.60 million in Q4 2025, translating to $0.81 per share, which is a significant increase from last year's loss of $8.78 million or $2.16 per share, indicating heightened financial pressures on the company.
- Annual Losses Widen: For the full year 2025, Aardvark's net loss expanded to $57.59 million, or $2.93 per share, compared to a loss of $20.59 million and $5.15 per share in the previous year, reflecting ongoing challenges in research and operational expenditures.
- Pipeline Update: Following unexpected reversible cardiac observations in a healthy volunteer trial, Aardvark has voluntarily paused the Phase 3 trials for ARD-101 and related trials for ARD-201, with further guidance expected in Q2 2026, highlighting the company's commitment to safety.
- Strong Cash Position: As of December 31, 2025, Aardvark had $110 million in cash and short-term investments, which is projected to fund operations into Q2 2027, demonstrating financial resilience despite ongoing R&D challenges.
See More
Aardvark Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Aardvark Therapeutics reported a Q4 GAAP EPS of -$0.81, beating expectations by $0.02, indicating improvements in financial management that may boost investor confidence.
- Significant Cash Reserves: As of December 31, 2025, Aardvark's cash and short-term investments totaled $110 million, a 49.9% increase from $73.7 million in 2024, providing a stronger financial foundation for future growth.
- Sufficient Operating Funds: Based on current operating plans, Aardvark believes its existing cash and short-term investments will fund operations into Q2 2027, demonstrating robustness in financial management and operational planning.
- Executive Appointment: Aardvark Therapeutics appointed Derrick C. Li as Chief Business Officer, aiming to enhance the company's business strategy and market expansion capabilities, potentially laying the groundwork for future growth.
See More
Aardvark Therapeutics Shares Plunge After Trial Halt
- Trial Suspension: On March 2, 2026, Aardvark Therapeutics announced the halt of its HERO trial for ARD-101 in Prader-Willi Syndrome patients, resulting in a 56% drop in share price, equating to a loss of $7.02 per share, indicating a severe blow to investor confidence in the company's future.
- Safety Risk Warning: The company cited “reversible cardiac observations” as the reason for pausing the trial, a revelation that not only dashed investor expectations but also raised concerns among analysts, prompting several to sharply reduce or suspend their price targets for the stock.
- Investor Investigation Launched: In light of the drastic market reaction, Hagens Berman law firm has initiated an investigation into whether Aardvark misled investors regarding the safety and efficacy data of ARD-101, potentially exposing the company to legal risks.
- FDA Communication Issues: Aardvark previously claimed good communication with the FDA and emphasized ARD-101's “tolerable safety profile,” but this incident has raised questions about the transparency of its disclosures, which could impact future investor trust and the company's reputation.
See More
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56%
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, the suspension of its HERO trial, resulting in a share price drop of $7.02 (-56%), a decision driven by serious safety risks identified as 'reversible cardiac observations,' which directly undermined investor confidence in the company's future prospects.
- Investor Investigation Launched: In light of the severe market reaction, Hagens Berman law firm has initiated an investigation into whether Aardvark misled investors regarding the safety and efficacy disclosures of ARD-101, potentially violating federal securities laws, further exacerbating investor anxiety.
- FDA Communication Issues: Aardvark previously claimed smooth communication with the FDA and emphasized ARD-101 as a 'first-in-class' drug; however, the trial suspension has raised questions about the transparency and accuracy of its communications with the FDA, which could impact future regulatory approval processes.
- Analyst Downgrades: Following the emergence of cardiac safety signals, several analysts have begun to sharply reduce or suspend their price targets for Aardvark, reflecting a pessimistic sentiment in the market regarding the company's outlook, which may lead to further declines in share price.
See More
Aardvark Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud or unlawful business practices, which could undermine investor confidence and lead to further stock price declines.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations found in a healthy volunteer study, potentially delaying product launch timelines and impacting future revenues.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price plummeted by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, reflecting extreme market pessimism regarding the company's outlook.
- Legal Implications: Pomerantz LLP, a prominent securities litigation firm, may initiate a class action lawsuit against Aardvark if the investigation confirms wrongdoing, which would severely impact the company's reputation and financial standing.
See More
AARDVARK THERAPEUTICS INC: B. RILEY LOWERS TARGET PRICE FROM $32 TO $8
- Target Price Adjustment: B. Riley has cut the target price for Aardvark Therapeutics from $32 to $8.
- Market Impact: This significant reduction reflects a reassessment of the company's market position and potential.
See More
Aardvark Therapeutics Reports Wider Losses in Q4 and FY2025
- Dismal Financial Results: Aardvark Therapeutics reported a net loss of $17.60 million in Q4 2025, translating to $0.81 per share, which is a significant increase from last year's loss of $8.78 million or $2.16 per share, indicating heightened financial pressures on the company.
- Annual Losses Widen: For the full year 2025, Aardvark's net loss expanded to $57.59 million, or $2.93 per share, compared to a loss of $20.59 million and $5.15 per share in the previous year, reflecting ongoing challenges in research and operational expenditures.
- Pipeline Update: Following unexpected reversible cardiac observations in a healthy volunteer trial, Aardvark has voluntarily paused the Phase 3 trials for ARD-101 and related trials for ARD-201, with further guidance expected in Q2 2026, highlighting the company's commitment to safety.
- Strong Cash Position: As of December 31, 2025, Aardvark had $110 million in cash and short-term investments, which is projected to fund operations into Q2 2027, demonstrating financial resilience despite ongoing R&D challenges.
See More
Aardvark Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Aardvark Therapeutics reported a Q4 GAAP EPS of -$0.81, beating expectations by $0.02, indicating improvements in financial management that may boost investor confidence.
- Significant Cash Reserves: As of December 31, 2025, Aardvark's cash and short-term investments totaled $110 million, a 49.9% increase from $73.7 million in 2024, providing a stronger financial foundation for future growth.
- Sufficient Operating Funds: Based on current operating plans, Aardvark believes its existing cash and short-term investments will fund operations into Q2 2027, demonstrating robustness in financial management and operational planning.
- Executive Appointment: Aardvark Therapeutics appointed Derrick C. Li as Chief Business Officer, aiming to enhance the company's business strategy and market expansion capabilities, potentially laying the groundwork for future growth.
See More
